Showing results (51-60 of 188) with videos related to
Sort By:
Pageof 19
Gynecologic Oncology|December 1, 1989
Conservative management of primary cervical lymphoma using combination chemotherapy: a case reportC Johnston, E K Senekjian, M J Ratain, et al.Cancer Research|March 15, 1996
Pharmacokinetic modulation of irinotecan and metabolites by cyclosporin AE Gupta, A R Safa, X Wang, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 1, 1996
Limited sampling model for area under the concentration time curve of total topotecanH Minami, J H Beijnen, J Verweij, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1996
Limited-sampling models for irinotecan pharmacokinetics-pharmacodynamics: prediction of biliary index and intestinal toxicityR Mick, E Gupta, E E Vokes, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1991
Limited sampling models for doxorubicin pharmacokineticsM J Ratain, J Robert, W J van der VijghAmerican Journal of Hematology|January 1, 1988
Rapid response to 2'-deoxycoformycin in advanced hairy cell leukemia after failure of interferons alpha and gammaB C Lembersky, M J Ratain, C Westbrook, et al.American Journal of Clinical Oncology|June 17, 2000
A phase I study of liposomal doxorubicin (Doxil) with topotecanC W Ryan, G F Fleming, L Janisch, et al.Clinical Pharmacology and Therapeutics|April 18, 2008
Pharmacogenetic pathway analysis of irinotecanG L Rosner, J C Panetta, F Innocenti, et al.Cancer|April 1, 1993
A phase I study of subcutaneous recombinant interleukin-2 and interferon alfa-2aM J Ratain, E R Priest, L Janisch, et al.Leukemia & Lymphoma|January 1, 1994
Interferon treatment for hairy cell leukemia. An update on a cohort of 69 patients treated from 1983 to 1986R T Spielberger, R Mick, M J Ratain, et al.Pageof 19